Page 4 
Coalition 
"The IBC shall be a committee .. .that has the experience and expertise to 
assess the safety of proposed recombinant DNA research projects .. .Its memb- 
ership should include. . .disciplines relevant to recombinant DNA technology, 
biological safety and engineering. It is recommended that the IBC also in- 
clude members knowledgeable about such matters as applicable law, standards 
of professional conduct and ractice, community attitudes, and the environ- 
ment. It is recommended that at least one member be a non-doctoral person 
from a laboratory technical staff." (p. 33085 IV-A-2) 
The use of the word "recommend" rather than "directed" or "mandated" 
or "required" permits the IBC t s free rein to constitute their roster as 
they may desire. Further, the need for experts in epidemiology, virology, 
public health, industrial hygiene-, infectious disease, etc. is not ad- 
dressed. 
VII . Sanction and Comptiance 
The language employed in the area of sanctions and compliance is too 
weak to ensure compliance. "All NIH-funded projects involving recombinant 
DNA technology must comply with the NIH guidelines. Non-compliance may re- 
sult in suspension, limitation or termination of financial assistance for 
such projects and for other recombinant DNA research at the institution." 
VIII. Me.cha.ni6m jo ft Policy Change. 
Changes in policy are vested in the Director of the NIH. Unchecked, 
extensive powers governing recombinant DNA research which come under his 
purview include: 
“the power to revise and amend the Guidelines (p. 33086 IV-B-lb) 
“the power to certify new host-vector systems (p. 33086 IV-B-lc) 
“the power to permit exemptions from experimental 
prohibitions (p. 33086 IV-B-le) 
• [A-332] 
